Navigation Links
Malaria medication may help against 1 type of frontotemporal dementia
Date:2/2/2011

Frontotemporal dementia is caused by a breakdown of nerve cells in the frontal and temporal region of the brain (fronto-temporal lobe), which leads to, among other symptoms, a change in personality and behavior. The cause of some forms of frontotemporal dementia is a genetically determined reduction of a hormone-like growth factor, progranulin. Scientists around Dr. Anja Capell and Prof. Christian Haass have now shown that various drugs that are already on the market to treat malaria, angina pectoris or heart rhythm disturbances can increase the production of progranulin. Accordingly, these drugs are good candidates for treatment of this specific form of frontotemporal dementia. The work will be published in the online edition of the scientific journal Journal of Neuroscience on February 2nd, 2011.

Progranulin is needed in the human brain as a protective factor for sensitive nerve cells, too little progranulin therefore results in a progressive neuronal cell death. As for almost every other gene, there are also two copies of the progranulin gene in the cell. In patients with progranulin dependent frontotemporal dementia, one of the two copies is defective, leading to a 50% reduction in progranulin levels. To rescue the lack of progranulin, the Munich researchers tested various substances for their ability to stimulate the remaining progranulin production and identified a drug called bafilomycin (BafA1). They then examined the molecular mechanism underlying the impact of BafA1 on progranulin more closely. Growth factors such as progranulin are produced in cellular membrane inclusions, known as vesicles. BafA1 has an alkalizing effect on these vesicles: After administration of BafA1 the interior of the vesicles is less acidic and this increases the production of progranulin.

This observation encouraged the researchers to investigate further alkalizing substances for their ability to raise progranulin levels. Among the substances that passed the test were three drugs that are already on the market to treat various diseases: a medication for angina pectoris (bepridil), one for heart rhythm problems (amiodarone) and the widely used malaria drug chloroquine. Chloroquine increased the progranulin level not only in experiments with mouse cells to normal, but also in cells from patients with the defective progranulin gene.

In a clinical study in collaboration with the University of London, the team of Prof. Haass and Dr. Capell will now investigate whether chloroquine actually helps against progranulin dependent frontotemporal dementia. The human studies can be started very soon, as chloroquine has been used on countless patients, so that serious side effects are not to be expected. Even though the Munich scientists are optimistic, Prof. Haass warns against exaggerated hopes. "Experience shows that the step from cell and animal models to the patient is always connected with considerable difficulties. It will take several years until we know, whether chloroquine can be used as therapy for progranulin dependent frontotemporal dementia," says Haass.


'/>"/>

Contact: Katrin Weigmann
katrin.weigmann@dzne.de
49-228-433-02263
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Malaria modeling and control focus of workshop
2. Malaria-infected cells stiffen, block blood flow
3. New study examines immunity in emerging species of a major mosquito carrer of malaria
4. Researchers link cerebral malaria to epilepsy, behavior disorders
5. UC Riverside cell biologist to investigate how malaria parasite multiplies in red blood cells
6. International malaria research consortium tackles deadly disease
7. Genetic markers offer new clues about how malaria mosquitoes evade eradication
8. Malaria research begins to bite
9. Malarias newest pathway into human cells identified
10. Novartis and collaborators discover novel antimalarial drug candidate
11. New methods, new math speed detection of drug-resistant malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... 2016   Valencell , the leading innovator ... STMicroelectronics (NYSE: STM), a global semiconductor leader serving ... today the launch of a new, highly accurate ... includes ST,s compact SensorTile turnkey multi-sensor ... sensor system. Together, SensorTile and Benchmark deliver the ...
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions America ... management products and solutions and a cutting-edge manufacturer ... that it is offering seamless, integrated solutions that ... entrance products. The solutions provide IdentyTech,s customers with ... their facilities from crime and theft. ...
(Date:12/16/2016)... YORK , Dec. 16, 2016 The global wearable ... USD 12.14 billion by 2021 from USD 5.31 billion in 2016, ... ... is mainly driven by technological advancements in medical devices, launch of ... rising preference for wireless connectivity among healthcare providers, and increasing focus ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., today ... , Ph.D., as chief executive officer, as well ... Dr. Schmidt brings to ArmaGen more than 17 years ... and development of biotherapeutics and pharmaceuticals. ... the diverse experience and skillset necessary to lead ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical Informatics Association ... Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans ... policy. AMIA recommended that NIH earmark funding for researchers to produce and execute ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... FireflySci Inc. ... exponential rate. The tremendous growth is accounted to two main factors. The ... and the expanding network of vendors supplying FireflySci products all around the world. , ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 ... to reach USD 92.9 billion by 2025, according ... Inc. Pharmaceutical industry has been adaptive of the ... as early as 2002. Among the services outsourced, ... forerunners. For instance, Johnson & Johnson was the ...
Breaking Biology Technology: